Access >
SubMenu
Treating cancer more accurately
The genetic diagnostic tools will be the result of our own development, or of alliances with third parties.
The knowledge of cancer increases continuously and Ferrer inCode has transformed this understanding into a practical tool to predict clinical outcome in breast cancer. MammaPrint® (developed by Agendia, The Netherlands), the 70 gene signature, is currently the most powerful Prognostict test of recurrence of breast cancer (Piccart, JNCI).
Ferrer inCode provides all health professionals in Spain a safe, early and achievable access to the latest findings in multi-gene based diagnostics.
Ferrer inCode Diagonal, 549 5ª planta, E-08029 Barcelona - Spain - Tel.: +34 93 600 37 00 - Fax: +34 93 490 70 78